Biocon hits new high on DGCI nod to market Itolizumab for Covid treatment

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru

Itolizumab will be manufactured and formulated as an intravenous injection at Biocon's bio-manufacturing facility at Biocon Park, Bengaluru https://ift.tt/2ZWKgCM July 12, 2020 at 06:20PM

Comments

Popular posts from this blog

US may impose tariffs on India, Italy for taxing internet firms like Google

No locus standi: India rejects US global religious freedom report